IRIS Accounts Production v24.2.0.383 Other Company accounts True false Pounds 1.3.23 29.2.24 29.2.24 FY FRS 102 Independent examiner Small companies regime for accounts Full Charities SORP true true true true false true false true 0 0 iso4217:GBPiso4217:USDiso4217:EURxbrli:sharesxbrli:pureutr:tonnesutr:kWh065119622023-02-28065119622024-02-29065119622023-03-012024-02-29065119622022-02-28065119622022-03-012023-02-28065119622023-02-2806511962ns0:CharitableCompanyLimitedByGuarantee2023-03-012024-02-2906511962ns15:PoundSterling2023-03-012024-02-2906511962ns11:FRS1022023-03-012024-02-2906511962ns11:IndependentExaminationCharity2023-03-012024-02-2906511962ns11:SmallCompaniesRegimeForAccounts2023-03-012024-02-2906511962ns11:FullAccounts2023-03-012024-02-2906511962ns11:CharitiesSORP2023-03-012024-02-2906511962ns16:EnglandWales2023-03-012024-02-2906511962ns11:RegisteredOffice2023-03-012024-02-2906511962ns0:Trustee12023-03-012024-02-2906511962ns0:Trustee22023-03-012024-02-2906511962ns0:Trustee32023-03-012024-02-2906511962ns11:CompanySecretary12023-03-012024-02-2906511962ns10:WithinOneYear2024-02-2906511962ns10:WithinOneYear2023-02-2806511962ns0:TotalUnrestrictedFunds2024-02-290651196222023-03-012024-02-29
REGISTERED COMPANY NUMBER: 06511962 (England and Wales)
REGISTERED CHARITY NUMBER: 1125916






Degenerative Encephalopathy Research
Group

Report of the Trustees and

Financial Statements

for the Year Ended 29 February 2024

Degenerative Encephalopathy Research
Group

Contents of the Financial Statements
for the year ended 29 February 2024










Page

Report of the Trustees 1

Independent Examiner's Report 3

Statement of Financial Activities 4

Balance Sheet 5

Notes to the Financial Statements 7

Degenerative Encephalopathy Research
Group (Registered number: 06511962)

Report of the Trustees
for the year ended 29 February 2024



The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 29 February 2024. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

OBJECTIVES AND ACTIVITIES
Objectives and aims
The objects of the Charity is to benefit the public by funding, undertaking, furthering and publishing biomedical research to determine the molecular causes and facilitate the early diagnosis, therapy and prevention of the group of transmissible degenerative diseases of the central nervous system of which Creuzfeldt Jakob disease (CJD) in humans and scrapie in animals are examples and of similar diseases not known to be transmissible of which Alzheimer's dementia and Parkinson's disease are human examples.

ACHIEVEMENT AND PERFORMANCE
Charitable activities
The Charity's primary aim during the period has been to increase its profile. The Charity has also been looking for suitable locations in which its reserves can be used to fund research.

FINANCIAL REVIEW
Reserves policy
The Trustees have considered the level of reserves they wish to retain, appropriate to the Charity's needs. This is based on the Charity's size and the level of financial commitment held.

As stated above, the Charity has not funded any research since its incorporation and it will continue to maintain reserves until the funding is used to fulfil its objectives.

At the year end, the unrestricted reserves were £240,626.

STRUCTURE, GOVERNANCE AND MANAGEMENT
Governing document
The charity is controlled by its governing document, the memorandum and articles of association, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

REFERENCE AND ADMINISTRATIVE DETAILS
Registered Company number
06511962 (England and Wales)

Registered Charity number
1125916

Registered office
Broats Farm
Swainsea Lane
Pickering
North Yorkshire
YO18 8PW

Trustees
Mr P T Mills
Mr D Body
Dr A C Maddocks


Degenerative Encephalopathy Research
Group (Registered number: 06511962)

Report of the Trustees
for the year ended 29 February 2024


REFERENCE AND ADMINISTRATIVE DETAILS
Company Secretary
Mr D Body

Independent Examiner
SMH Jolliffe Cork Ltd
Chartered Accountants
33 George Street
Wakefield
West Yorkshire
WF1 1LX

This report has been prepared in accordance with the special provisions of Part 15 of the Companies Act 2006 relating to small companies.

Approved by order of the board of trustees on 6 August 2024 and signed on its behalf by:





Mr D Body - Secretary

Independent Examiner's Report to the Trustees of
Degenerative Encephalopathy Research
Group


Independent examiner's report to the trustees of Degenerative Encephalopathy Research Group ('the Company')
I report to the charity trustees on my examination of the accounts of the Company for the year ended 29 February 2024.

Responsibilities and basis of report
As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under Section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under Section 145(5) (b) of the 2011 Act.

Independent examiner's statement
I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by Section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of Section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.








J Crossley FCA

SMH Jolliffe Cork Ltd
Chartered Accountants
33 George Street
Wakefield
West Yorkshire
WF1 1LX

6 August 2024

Degenerative Encephalopathy Research
Group

Statement of Financial Activities
for the year ended 29 February 2024

2024 2023
Unrestricted
fund Total funds
Notes £ £
INCOME AND ENDOWMENTS FROM
Donations and legacies 9 -

Investment income 2 5,318 1,223
Total 5,327 1,223

EXPENDITURE ON


Other 688 506

NET INCOME 4,639 717


RECONCILIATION OF FUNDS
Total funds brought forward 235,987 235,270

TOTAL FUNDS CARRIED FORWARD 240,626 235,987

Degenerative Encephalopathy Research
Group (Registered number: 06511962)

Balance Sheet
29 February 2024

2024 2023
Unrestricted
fund Total funds
Notes £ £
CURRENT ASSETS
Cash at bank 241,256 236,437

CREDITORS
Amounts falling due within one year 5 (630 ) (450 )

NET CURRENT ASSETS 240,626 235,987

TOTAL ASSETS LESS CURRENT
LIABILITIES

240,626

235,987

NET ASSETS 240,626 235,987
FUNDS 6
Unrestricted funds 240,626 235,987
TOTAL FUNDS 240,626 235,987

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 29 February 2024.


The members have not required the company to obtain an audit of its financial statements for the year ended 29 February 2024 in accordance with Section 476 of the Companies Act 2006.


The trustees acknowledge their responsibilities for
(a)ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
(b)preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.


Degenerative Encephalopathy Research
Group (Registered number: 06511962)

Balance Sheet - continued
29 February 2024

These financial statements have been prepared in accordance with the provisions applicable to charitable companies subject to the small companies regime.


The financial statements were approved by the Board of Trustees and authorised for issue on 6 August 2024 and were signed on its behalf by:





Mr P T Mills - Trustee





Mr D Body - Trustee

Degenerative Encephalopathy Research
Group

Notes to the Financial Statements
for the year ended 29 February 2024


1. ACCOUNTING POLICIES

Basis of preparing the financial statements
The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

Income
All income is recognised in the Statement of Financial Activities once the charity has entitlement to the funds, it is probable that the income will be received and the amount can be measured reliably.

Expenditure
Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably. Expenditure is accounted for on an accruals basis and has been classified under headings that aggregate all cost related to the category. Where costs cannot be directly attributed to particular headings they have been allocated to activities on a basis consistent with the use of resources.

Taxation
The charity is exempt from corporation tax on its charitable activities.

Fund accounting
Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

2. INVESTMENT INCOME
2024 2023
£ £
Deposit account interest 5,318 1,223


Degenerative Encephalopathy Research
Group

Notes to the Financial Statements - continued
for the year ended 29 February 2024


3. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 29 February 2024 nor for the year ended 28 February 2023.


Trustees' expenses

Trustees' expenses of £nil were incurred during the year ended 29 February 2024. (2023: £nil)

4. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES
Unrestricted
fund
£
INCOME AND ENDOWMENTS FROM

Investment income 1,223

EXPENDITURE ON


Other 506

NET INCOME 717


RECONCILIATION OF FUNDS
Total funds brought forward 235,270

TOTAL FUNDS CARRIED FORWARD 235,987


Degenerative Encephalopathy Research
Group

Notes to the Financial Statements - continued
for the year ended 29 February 2024


5. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR
2024 2023
£ £
Accruals and deferred income 630 450

6. MOVEMENT IN FUNDS
Net
movement
At 1.3.23 in funds At 29.2.24
£ £ £
Unrestricted funds
General fund 235,987 4,639 240,626

TOTAL FUNDS 235,987 4,639 240,626

Net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 5,327 (688 ) 4,639

TOTAL FUNDS 5,327 (688 ) 4,639


Comparatives for movement in funds

Net
movement
At 1.3.22 in funds At 28.2.23
£ £ £
Unrestricted funds
General fund 235,270 717 235,987

TOTAL FUNDS 235,270 717 235,987

Degenerative Encephalopathy Research
Group

Notes to the Financial Statements - continued
for the year ended 29 February 2024


6. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

Incoming Resources Movement
resources expended in funds
£ £ £
Unrestricted funds
General fund 1,223 (506 ) 717

TOTAL FUNDS 1,223 (506 ) 717

7. RELATED PARTY DISCLOSURES

There were no related party transactions for the year ended 29 February 2024.